Medco Lipitor Fact Sheet
Click here to load reader
-
Upload
loren-steffy -
Category
Documents
-
view
1.623 -
download
0
Transcript of Medco Lipitor Fact Sheet
Medco Fact Sheet: One Client's Choice for Branded over Generic
On November 12, 2011, The New York Times published a story incorrectly reporting
that Medco has forged an agreement with Pfizer ordering retail pharmacies to continue
dispensing branded Lipitor instead of generics – which, the story asserts, will raise costs
for plan sponsors, member, taxpayers and Medicare recipients. Nothing could be
further from the actual facts.
The Times story references a client-specific notice sent by Medco to retail
pharmacies on behalf of a single health plan client that has chosen to work with
Pfizer directly to continue using branded Lipitor rather than the generic product
during the generic exclusivity period.
This is a client specific decision that Medco is administering at its direction.
All rebates generated by this specific client’s program are retained by that client.
Medco retains no rebates.
The story also failed to note that members of this health plan will pay the
generic co-payment for the branded Lipitor.
The Times story does not reflect Medco’s generic strategy related to Lipitor, which
delivers to our clients and members the option that maximizes value through the
exclusivity period and reinforces our commitment to generics as a means of lowering
costs of providing high-quality care. Medco’s Lipitor strategy, which will be adopted by
more than 99 percent of its clients, provides that:
Retail pharmacies will be able to dispense generic Lipitor and will not be
restricted from dispensing the generic.
To ensure adequate supplies immediately upon patent expiration, Medco will use
Lipitor as its “house generic” (e.g., branded Lipitor will be dispensed as the
generic product)
In all cases, members with prescriptions that allow for generic substitution will
pay the generic co-payments and clients will pay the same amount as specified by
their contracts, independent of whether the generic or the branded Lipitor used as
the “house generic” is dispensed.
The New York Times quoted sources that are long-time PBM adversaries who provided
misleading, inaccurate and/or incomplete information to create a negative perception.